0 CHECKOUT

Ovarian Cancer - Pipeline Review, H1 2015

  • ID: 3345028
  • June 2015
  • 1530 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 3-V Biosciences, Inc.
  • Basilea Pharmaceutica AG
  • CytRx Corporation
  • ImmunoFrontier, Inc.
  • Oasmia Pharmaceutical AB
  • Prima BioMed Ltd.
  • MORE

Ovarian Cancer - Pipeline Review, H1 2015

Summary

the, ‘Ovarian Cancer - Pipeline Review, H1 2015’, provides an overview of the Ovarian Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.

the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3-V Biosciences, Inc.
  • Basilea Pharmaceutica AG
  • CytRx Corporation
  • ImmunoFrontier, Inc.
  • Oasmia Pharmaceutical AB
  • Prima BioMed Ltd.
  • MORE

Introduction
Ovarian Cancer Overview
Therapeutics Development
Ovarian Cancer – Therapeutics under Development by Companies
Ovarian Cancer – Therapeutics under Investigation by Universities/Institutes
Ovarian Cancer – Pipeline Products Glance
Ovarian Cancer – Products under Development by Companies
Ovarian Cancer – Products under Investigation by Universities/Institutes
Ovarian Cancer – Companies Involved in Therapeutics Development
Ovarian Cancer – Therapeutics Assessment
Drug Profiles
Ovarian Cancer – Recent Pipeline Updates
Ovarian Cancer – Dormant Projects
Ovarian Cancer – Discontinued Products
Ovarian Cancer – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Ovarian Cancer, H1 2015
Number of Products under Development for Ovarian Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Development by Companies, H1 2015 (Contd..9)
Number of Products under Development by Companies, H1 2015 (Contd..10)
Number of Products under Development by Companies, H1 2015 (Contd..11)
Number of Products under Development by Companies, H1 2015 (Contd..12)
Number of Products under Development by Companies, H1 2015 (Contd..13)
Number of Products under Development by Companies, H1 2015 (Contd..14)
Number of Products under Development by Companies, H1 2015 (Contd..15)
Number of Products under Development by Companies, H1 2015 (Contd..16)
Number of Products under Development by Companies, H1 2015 (Contd..17)
Number of Products under Development by Companies, H1 2015 (Contd..18)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Development by Companies, H1 2015 (Contd..14)
Products under Development by Companies, H1 2015 (Contd..15)
Products under Development by Companies, H1 2015 (Contd..16)
Products under Development by Companies, H1 2015 (Contd..17)
Products under Development by Companies, H1 2015 (Contd..18)
Products under Development by Companies, H1 2015 (Contd..19)
Products under Development by Companies, H1 2015 (Contd..20)
Products under Development by Companies, H1 2015 (Contd..21)
Products under Development by Companies, H1 2015 (Contd..22)
Products under Development by Companies, H1 2015 (Contd..23)
Products under Development by Companies, H1 2015 (Contd..24)
Products under Development by Companies, H1 2015 (Contd..25)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Ovarian Cancer – Pipeline by 3-V Biosciences, Inc., H1 2015
Ovarian Cancer – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015
Ovarian Cancer – Pipeline by AbbVie Inc., H1 2015
Ovarian Cancer – Pipeline by Abeona Therapeutics, Inc. , H1 2015
Ovarian Cancer – Pipeline by AbGenomics International, Inc., H1 2015
Ovarian Cancer – Pipeline by Acceleron Pharma, Inc., H1 2015
Ovarian Cancer – Pipeline by Adaptimmune Limited, H1 2015
Ovarian Cancer – Pipeline by Aduro BioTech, Inc., H1 2015
Ovarian Cancer – Pipeline by Advanced Accelerator Applications SA, H1 2015
Ovarian Cancer – Pipeline by Advantagene, Inc., H1 2015
Ovarian Cancer – Pipeline by Advaxis, Inc., H1 2015
Ovarian Cancer – Pipeline by Advenchen Laboratories, LLC, H1 2015
Ovarian Cancer – Pipeline by Aeterna Zentaris Inc., H1 2015
Ovarian Cancer – Pipeline by Agilvax, Inc., H1 2015
Ovarian Cancer – Pipeline by Alchemia Limited, H1 2015
Ovarian Cancer – Pipeline by Alethia Biotherapeutics Inc., H1 2015
Ovarian Cancer – Pipeline by Almac Discovery Limited, H1 2015
Ovarian Cancer – Pipeline by Ambrx, Inc., H1 2015
Ovarian Cancer – Pipeline by Amgen Inc., H1 2015
Ovarian Cancer – Pipeline by Amorfix Life Sciences Ltd., H1 2015
Ovarian Cancer – Pipeline by Anavex Life Sciences Corp., H1 2015
Ovarian Cancer – Pipeline by Angstrom Pharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by ANP Technologies, Inc., H1 2015
Ovarian Cancer – Pipeline by Aphios Corporation, H1 2015
Ovarian Cancer – Pipeline by Aposense Ltd., H1 2015
Ovarian Cancer – Pipeline by Aprea AB, H1 2015
Ovarian Cancer – Pipeline by arGEN-X BV, H1 2015
Ovarian Cancer – Pipeline by Armour Therapeutics Inc., H1 2015
Ovarian Cancer – Pipeline by Arog Pharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by Array BioPharma Inc., H1 2015
Ovarian Cancer – Pipeline by Arrien Pharmaceuticals, LLC, H1 2015
Ovarian Cancer – Pipeline by Ascenta Therapeutics, Inc., H1 2015
Ovarian Cancer – Pipeline by Astellas Pharma Inc., H1 2015
Ovarian Cancer – Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by AstraZeneca Plc, H1 2015
Ovarian Cancer – Pipeline by Atara Biotherapeutics, Inc., H1 2015
Ovarian Cancer – Pipeline by ATLAB Pharma SAS, H1 2015
Ovarian Cancer – Pipeline by AVAX Technologies, Inc., H1 2015
Ovarian Cancer – Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by Avipep Pty Ltd, H1 2015
Ovarian Cancer – Pipeline by Azaya Therapeutics Incorporated, H1 2015
Ovarian Cancer – Pipeline by Basilea Pharmaceutica AG, H1 2015
Ovarian Cancer – Pipeline by Bavarian Nordic A/S, H1 2015
Ovarian Cancer – Pipeline by Bayer AG, H1 2015
Ovarian Cancer – Pipeline by BioCancell Ltd, H1 2015
Ovarian Cancer – Pipeline by BioMarin Pharmaceutical Inc., H1 2015
Ovarian Cancer – Pipeline by BioMoti Limited, H1 2015
Ovarian Cancer – Pipeline by Bionomics Limited, H1 2015
Ovarian Cancer – Pipeline by BioNovion B.V., H1 2015
Ovarian Cancer – Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by Bioo Therapeutics, H1 2015
Ovarian Cancer – Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2015
Ovarian Cancer – Pipeline by Boston Biomedical, Inc., H1 2015
Ovarian Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2015
Ovarian Cancer – Pipeline by Caladrius Biosciences, Inc. , H1 2015
Ovarian Cancer – Pipeline by Calithera Biosciences, Inc., H1 2015
Ovarian Cancer – Pipeline by CASI Pharmaceuticals Inc., H1 2015
Ovarian Cancer – Pipeline by Cavion LLC, H1 2015
Ovarian Cancer – Pipeline by cCAM Biotherapeutics Ltd., H1 2015
Ovarian Cancer – Pipeline by Celgene Corporation, H1 2015
Ovarian Cancer – Pipeline by Celldex Therapeutics, Inc., H1 2015
Ovarian Cancer – Pipeline by Cellectar Biosciences, Inc., H1 2015
Ovarian Cancer – Pipeline by Cellular Biomedicine Group, Inc., H1 2015
Ovarian Cancer – Pipeline by Celon Pharma Sp. z o.o., H1 2015
Ovarian Cancer – Pipeline by Celsion Corporation, H1 2015
Ovarian Cancer – Pipeline by Celyad, H1 2015
Ovarian Cancer – Pipeline by Ceronco Biosciences, H1 2015
Ovarian Cancer – Pipeline by Cerulean Pharma, Inc., H1 2015
Ovarian Cancer – Pipeline by Chikujee Therapeutics, H1 2015
Ovarian Cancer – Pipeline by Chipscreen Biosciences Ltd, H1 2015
Ovarian Cancer – Pipeline by Clevexel Pharma SAS, H1 2015
Ovarian Cancer – Pipeline by Clovis Oncology, Inc., H1 2015
Ovarian Cancer – Pipeline by Cold Genesys, Inc., H1 2015
Ovarian Cancer – Pipeline by Critical Outcome Technologies Inc., H1 2015
Ovarian Cancer – Pipeline by CritiTech, Inc., H1 2015
Ovarian Cancer – Pipeline by CTI BioPharma Corp., H1 2015
Ovarian Cancer – Pipeline by Curis, Inc., H1 2015
Ovarian Cancer – Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by CytRx Corporation, H1 2015
Ovarian Cancer – Pipeline by CZ BioMed Corp, H1 2015
Ovarian Cancer – Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Ovarian Cancer – Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015
Ovarian Cancer – Pipeline by DEKK-TEC, Inc., H1 2015
Ovarian Cancer – Pipeline by Eisai Co., Ltd., H1 2015
Ovarian Cancer – Pipeline by Eli Lilly and Company, H1 2015
Ovarian Cancer – Pipeline by Endocyte, Inc., H1 2015
Ovarian Cancer – Pipeline by EntreChem, S.L., H1 2015
Ovarian Cancer – Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by Esperance Pharmaceuticals, Inc., H1 2015
Ovarian Cancer – Pipeline by Exelixis, Inc., H1 2015
Ovarian Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Ovarian Cancer – Pipeline by Fortress Biotech, Inc., H1 2015
Ovarian Cancer – Pipeline by Fujifilm Corporation, H1 2015
Ovarian Cancer – Pipeline by Galena Biopharma, Inc., H1 2015
Ovarian Cancer – Pipeline by Galileo Research s.r.l., H1 2015
Ovarian Cancer – Pipeline by GamaMabs Pharma S.A., H1 2015
Ovarian Cancer – Pipeline by Ganymed Pharmaceuticals AG, H1 2015
Ovarian Cancer – Pipeline by Genentech, Inc., H1 2015
Ovarian Cancer – Pipeline by Generex Biotechnology Corporation, H1 2015
Ovarian Cancer – Pipeline by Genmab A/S, H1 2015
Ovarian Cancer – Pipeline by GlaxoSmithKline Plc, H1 2015
Ovarian Cancer – Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015
Ovarian Cancer – Pipeline by GlycoNex Inc., H1 2015
Ovarian Cancer – Pipeline by Glycotope GmbH, H1 2015
Ovarian Cancer – Pipeline by GP Pharm, S.A., H1 2015
Ovarian Cancer – Pipeline by Gradalis Inc., H1 2015
Ovarian Cancer – Pipeline by Halozyme Therapeutics, Inc., H1 2015
Ovarian Cancer – Pipeline by Heat Biologics, Inc., H1 2015
Ovarian Cancer – Pipeline by Hemispherx Biopharma, Inc., H1 2015
Ovarian Cancer – Pipeline by Huabo Biopharm Co., Ltd., H1 2015
Ovarian Cancer – Pipeline by Ignyta, Inc., H1 2015

List of Figures
Number of Products under Development for Ovarian Cancer, H1 2015
Number of Products under Development for Ovarian Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

3-V Biosciences, Inc.
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc.
Abeona Therapeutics, Inc.
AbGenomics International, Inc.
Acceleron Pharma, Inc.
Adaptimmune Limited
Aduro BioTech, Inc.
Advanced Accelerator Applications SA
Advantagene, Inc.
Advaxis, Inc.
Advenchen Laboratories, LLC
Aeterna Zentaris Inc.
Agilvax, Inc.
Alchemia Limited
Alethia Biotherapeutics Inc.
Almac Discovery Limited
Ambrx, Inc.
Amgen Inc.
Amorfix Life Sciences Ltd.
Anavex Life Sciences Corp.
Angstrom Pharmaceuticals, Inc.
ANP Technologies, Inc.
Aphios Corporation
Aposense Ltd.
Aprea AB
arGEN-X BV
Armour Therapeutics Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Atara Biotherapeutics, Inc.
ATLAB Pharma SAS
AVAX Technologies, Inc.
AVEO Pharmaceuticals, Inc.
Avipep Pty Ltd
Azaya Therapeutics Incorporated
Basilea Pharmaceutica AG
Bavarian Nordic A/S
Bayer AG
BioCancell Ltd
BioMarin Pharmaceutical Inc.
BioMoti Limited
Bionomics Limited
BioNovion B.V.
BioNumerik Pharmaceuticals, Inc.
Bioo Therapeutics
Biscayne Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Calithera Biosciences, Inc.
CASI Pharmaceuticals Inc.
Cavion LLC
cCAM Biotherapeutics Ltd.
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Cellular Biomedicine Group, Inc.
Celon Pharma Sp. z o.o.
Celsion Corporation
Celyad
Ceronco Biosciences
Cerulean Pharma, Inc.
Chikujee Therapeutics
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Clovis Oncology, Inc.
Cold Genesys, Inc.
Critical Outcome Technologies Inc.
CritiTech, Inc.
CTI BioPharma Corp.
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
CytRx Corporation
CZ BioMed Corp
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
DEKK-TEC, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Endocyte, Inc.
EntreChem, S.L.
Epirus Biopharmaceuticals, Inc.
Esperance Pharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Fortress Biotech, Inc.
Fujifilm Corporation
Galena Biopharma, Inc.
Galileo Research s.r.l.
GamaMabs Pharma S.A.
Ganymed Pharmaceuticals AG
Genentech, Inc.
Generex Biotechnology Corporation
Genmab A/S
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GlycoNex Inc.
Glycotope GmbH
GP Pharm, S.A.
Gradalis Inc.
Halozyme Therapeutics, Inc.
Heat Biologics, Inc.
Hemispherx Biopharma, Inc.
Huabo Biopharm Co., Ltd.
Ignyta, Inc.
Ildong Pharmaceutical Co., Ltd.
IMMD Inc.
Immune Design Corp.
ImmunoCellular Therapeutics, Ltd.
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunotope, Inc.
Immunovaccine, Inc.
Incyte Corporation
Innate Immunotherapeutics Limited
Innate Pharma SA
INSYS Therapeutics, Inc.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Laboratoire HRA Pharma
Lee's Pharmaceutical Holdings Limited
LegoChem Biosciences, Inc
Lymphocyte Activation Technologies, S.A.
MabVax Therapeutics Holdings, Inc.
Mebiopharm Co., Ltd.
Medestea Research & Production S.p.A.
MediaPharma s.r.l.
MedImmune, LLC
MEI Pharma, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Mission Therapeutics Ltd
MolMed S.p.A.
Morphotek, Inc.
Mundipharma International Ltd
Natco Pharma Limited
Nektar Therapeutics
Nemucore Medical Innovations, Inc.
Neurimmune Holding AG
Northwest Biotherapeutics, Inc.
Novartis AG
NuCana BioMed Limited
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Omeros Corporation
Omnitura Therapeutics Inc.
Oncobiologics, Inc.
Oncodesign SA
Oncogenex Pharmaceuticals, Inc.
OncoHoldings, Inc.
Oncolix, Inc.
Oncology Research International Limited
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Oncos Therapeutics Ltd.
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Onyx Pharmaceuticals, Inc.
Optimum Therapeutics, LLC
ORCA Therapeutics B.V.
OSE Pharma SA
Otsuka Holdings Co., Ltd.
Oxford BioMedica Plc
Oxford BioTherapeutics Ltd
OXiGENE, Inc.
Panacela Labs, Inc.
PEP-Therapy SAS
Pfizer Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Pharmicell Co., Ltd.
Polaris Pharmaceuticals, Inc.
Polyplus-transfection SA
Pono Pharma
Precision Biologics, Inc.
Prima BioMed Ltd.
PsiOxus Therapeutics Limited
Puma Biotechnology, Inc.
Qu Biologics Inc.
Quantum Pharmaceuticals
Quest PharmaTech Inc.
Recepta Biopharma S.A.
Rexahn Pharmaceuticals, Inc.
Rigontec GmbH
Rosetta Genomics, Ltd.
Samyang Holdings Corporation
Sanofi
Sanofi Pasteur SA
Scancell Holdings Plc
Serina Therapeutics, Inc.
Sigma-Tau S.p.A.
Soricimed Biopharma Inc.
Sotio a.s.
Spectrum Pharmaceuticals, Inc.
Sphaera Pharma Pvt. Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Synta Pharmaceuticals Corp.
Tactic Pharma, LLC
Takeda Pharmaceutical Company Limited
TapImmune Inc.
Tesaro, Inc.
TetraLogic Pharmaceuticals
Theravectys S.A.
TRACON Pharmaceuticals, Inc.
Trojantec ltd.
TVAX Biomedical, Inc.
ValiRx Plc
Vascular Biogenics Ltd.
Vaxeal Holding SA
VentiRx Pharmaceuticals, Inc.
Verastem, Inc.
VG Life Sciences, Inc.
VioQuest Pharmaceuticals, Inc.
ViraTherapeutics GmbH
Viventia Biotechnologies Inc.
Welichem Biotech Inc.
Zensun (Shanghai) Sci & Tech Co., Ltd.
ZIOPHARM Oncology, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Almac Diagnostics Group
  • Pfizer Inc.
  • Astrazeneca PLC
  • Hologic Inc.
  • Roche Diagnostics Ltd.
  • Bristol-Myers Squibb